导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 11.81% | 750/4766 |
| 近一周 | 0.25% | 692/5456 |
| 近一月 | -6.19% | 4068/5412 |
| 近一季 | -11.20% | 3876/5222 |
| 近半年 | 11.65% | 516/4911 |
| 近一年 | 15.52% | 774/4391 |
| 近两年 | 160.86% | 186/2953 |
| 近三年 | 116.34% | 113/2252 |
| 成立以来 | 38.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.18% 4060/4961 |
51.29% 571/5312 |
- - |
- - |
| 2025 | 63.21% 174/4813 |
4.99% 851/3635 |
1.16% 2439/4076 |
54.53% 214/4524 |
-0.56% 2540/4813 |
| 2024 | 19.82% 501/3463 |
-1.46% 1231/2808 |
-2.90% 1271/3014 |
14.31% 2010/3129 |
9.55% 322/3463 |
| 2023 | 10.60% 93/2656 |
36.19% 52/2280 |
-2.96% 725/2385 |
-13.60% 2156/2515 |
-3.15% 614/2655 |
| 2022 | -33.20% 1698/2207 |
-19.60% 1478/1919 |
-3.33% 1812/2016 |
-19.66% 1800/2113 |
6.97% 337/2208 |
| 2021 | 8.50% 474/1822 |
-6.22% 986/1255 |
13.49% 288/1330 |
-7.75% 1080/1466 |
10.50% 104/1822 |
| 2020 | - - |
- - |
- - |
-11.00% 1135/1164 |
-0.36% 1073/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 华夏中证人工智能主题ETF联接C VS. 长安沪深300非周期A(740101) |